logo
  

Bunge Turns To Profit In Q3 - Quick Facts

Bunge Limited's (BG) net income available to common shareholders for the third-quarter 2014 was $284 million, compared to a loss of $165 million in the year ago quarter. On a per share basis, net income was $1.90 compared to a loss of $1.13 in the previous year.

Adjusted net income per share from continuing operations dropped to $1.31 from $1.89 last year.

Soren Schroder, Bunge's Chief Executive Officer, stated, "Third-quarter results were lower than last year; however, Bunge is in a strong position to meet or exceed our full-year, combined return target of 1.5 points above cost of capital in Agribusiness and Food & Ingredients.

Net sales for the quarter were $13.676 billion lower than last year's $14.701 billion.

Analysts polled by Thomson Reuters expected the company to report earnings of $1.93 per share and revenues of $15.33 billion for the quarter. Analysts' estimates typically exclude special items.

The company expects to have a strong fourth quarter. In Agribusiness, record U.S. harvests in combination with extremely slow farmer selling in South America and strong demand from the livestock sector have driven U.S. crush margins to historically strong levels.

In Food & Ingredients the company expects another record year. The fourth quarter is the seasonally strong holiday period when demand for flours, vegetable oils, margarines and shortenings increases. It will also have additional contributions from its performance improvement initiatives and its new wheat mills in Mexico.

In Sugar & Bioenergy, the company expects breakeven full-year segment EBIT and are managing the business to be free cash flow neutral.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT